GIST Support Wiki

 

Imatinib mesylate (sold as Gleevec in the USA and Glivec elsewhere) is the first effective treatment for gastrointestinal stromal tumor (GIST). The drug is manufactured by Novartis Pharmaceuticals of Basel, Switzerland and New Hanover, New Jersey. It was approved by the FDA in February 2002 for use in metastatic or unresectable (inoperable) gastrointestinal stromal tumor. Imatinib (Gleevec) is the first marketed molecularly targeted therapy for cancer. This means that the drug affects only those cells that express highly specific targets, in contrast to conventional cancer chemotherapies that affect all fast-growing cells in the body. The targets of imatinib in GIST patients are two growth-factor receptors named KIT and PDGFRA. The drug is also used against chronic myelogenous leukemia, a disease in which affected patients have an abnormal protein called BCR-ABL that is targeted by imatinib. [1]

Information from Novartis Oncology

General Gleevec information


Subpages about Gleevec (click to link)

Blood trough level test for Gleevec concentration

Gleevec Side Effects

Gleevec Interactions

Gleevec and Dental Surgery

Iron Content of Gleevec Pills

Gleevec with Complementary and Alternative Medicines

Dr. Hohenberger's essay on ACOSOG Z9001 - Adjuvant Gleevec

Prelim results of ADJUVANT GLEEVEC - POST SURGERY study - 11/3/2007